Outlook Therapeutics (OTLK) Earnings Date, Estimates & Call Transcripts → The Only Energy Play You Should Be Looking At (From Wealthpin Pro) (Ad) Free OTLK Stock Alerts $6.79 -0.25 (-3.55%) (As of 06/7/2024 08:52 PM ET) Add Compare Share Share EarningsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Earnings SummaryUpcoming Earnings DateAug. 12EstimatedActual EPS (May. 15) -$1.55 Missed By -$0.67 Consensus EPS (May. 15) -$0.88 Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueOTLK Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.OTLK Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Crypto 101 MediaThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay attention to above all others: Venture capital firms. You want to follow venture capital money into cryptocurrencies before anyone gets word of what’s happening.Click here for all the details… Outlook Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20243($0.05)($0.04)($0.05)Q2 20243($1.28)($0.42)($0.88)Q3 20243($1.09)($0.64)($0.86)Q4 20243($0.89)($0.61)($0.71)FY 202412($3.31)($1.71)($2.50)Q1 20251($1.00)($1.00)($1.00)Q2 20251($0.50)($0.50)($0.50)Q3 20251($0.31)($0.31)($0.31)Q4 20251($0.31)($0.31)($0.31)FY 20254($2.12)($2.12)($2.12)OTLK Earnings Date and InformationOutlook Therapeutics last announced its earnings data on May 15th, 2024. The reported ($1.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.88) by $0.67. Outlook Therapeutics has generated ($11.41) earnings per share over the last year (($11.41) diluted earnings per share). Earnings for Outlook Therapeutics are expected to grow in the coming year, from ($4.02) to ($2.44) per share. Outlook Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, August 12th, 2024 based off prior year's report dates.Read More Outlook Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript 8/12/2024(Estimated)------- 5/15/2024Q2 2024($0.88)($1.55)($0.67)$4.91--2/14/2024Q1 2024($1.00)($0.80)+$0.20($0.04)--12/22/2023Q4 2023($1.00)($1.00)-($0.05)--8/14/2023Q3 2023($0.80)($1.60)($0.80)($0.08)--5/15/2023Q2 2023($1.20)($0.60)+$0.60($0.03)--2/14/2023Q1 2023($0.80)($1.60)($0.80)($0.08)--Top 5 AI Stocks to Buy for 2024 (Ad)The electric vehicle boom is accelerating – and fast.Click to View The 5 Best AI Stocks to Invest In8/10/2022Q3 2022($1.60)($1.60)-($0.08)--5/13/2022Q2 2022($1.40)($1.80)($0.40)($0.09)-- 2/13/2022Q1 2022($1.20)($1.60)($0.40)($0.08)-- 12/22/2021Q3 2021($1.20)($1.80)($0.60)($0.08)--8/12/2021Q2 2021($1.40)($1.40)-($0.07)--5/14/2021Q1 2021($2.00)($1.80)+$0.20($0.09)--2/16/2021Q4 2020($1.60)($2.40)($0.80)($0.12)--12/22/2020Q3 2020($1.60)($2.60)($1.00)---8/14/2020Q3 2020($1.40)($0.60)+$0.80($0.03)--5/15/2020Q2 2020($2.00)($7.20)($5.20)($0.36)--2/14/2020Q1 2020-($5.80)($5.80)$0.04--12/19/2019Q4 2019($6.20)($2.40)+$3.80($0.24)$0.63 million$5.85 million8/14/2019Q3($7.40)($4.80)+$2.60($0.28)$0.73 million$0.58 million Outlook Therapeutics Earnings - Frequently Asked Questions When is Outlook Therapeutics's earnings date? Outlook Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, August 12th, 2024 based off last year's report dates. Learn more on OTLK's earnings history. Did Outlook Therapeutics beat their earnings estimates last quarter? In the previous quarter, Outlook Therapeutics (NASDAQ:OTLK) missed the analysts' consensus estimate of ($0.88) by $0.67 with a reported earnings per share (EPS) of ($1.55). Learn more on analysts' earnings estimate vs. OTLK's actual earnings. How much profit does Outlook Therapeutics generate each year? Outlook Therapeutics (NASDAQ:OTLK) has a recorded net income of -$58.98 million. OTLK has generated -$11.41 earnings per share over the last four quarters. What is Outlook Therapeutics's EPS forecast for next year? Outlook Therapeutics's earnings are expected to grow from ($4.02) per share to ($2.44) per share in the next year. More Earnings Resources from MarketBeat Related Companies: Champions Oncology Earnings Protara Therapeutics Earnings Brainstorm Cell Therapeutics Earnings Valneva Earnings iTeos Therapeutics Earnings Lexeo Therapeutics Earnings Kyverna Therapeutics Earnings Adaptive Biotechnologies Earnings Cabaletta Bio Earnings Editas Medicine Earnings Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: CrowdStrike's Earnings: Consolidation and AI-Driven Growth The Most Upgraded Stocks After the Q1 Earnings Season ZIM Shipping Stock Forecast, Earnings Triggers a BuyAmerican Superconductor's Earnings Surge, Future Growth ExpectedHormel: A Potential Buy Despite Post-Earnings DeclineCanopy Growth’s Earnings: Profitability Despite Industry ShiftsAbercrombie & Fitch First Quarter Earnings Surge to New Heights This page (NASDAQ:OTLK) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersIt's time to ween off Chinese lithium!As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promi...Smallcaps Daily | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredYou won't believe what Citigroup just did to it's depositorsThe FEDNOW Biden Dollar ends cash in a matter of WEEKS Stumbling Biden's dollar next phases begins Oct 21st...American Alternative | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredRSVP: Charles Payne’s Cash Flow WorkshopDid you know you could "cash flow" the stocks in your portfolio? Without selling a single share of stock? ...Unstoppable Prosperity | Sponsored Adding Choose a watchlist: Watchlist My Default Watchlist Adding Outlook Therapeutics, Inc. You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Share Outlook Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.